While the primary study outcome, percentage of heavy drinking days, was lower, it did not reach statistical significance upon ABT-436 treatment compared to placebo, whereas the secondary endpoint, the percentage of abstinent days, significantly increased with ABT-436 treatment.
← all excerpts
Off-label and investigational drugs in the treatment of alcohol use disorder: A critical review.
1
—
—